Nonpharmacologic effects of botulinum toxin on the life quality of patients with spasmodic dysphonia

Laryngoscope

Volumn 117, Issue 10, 2007, Pages 1888-1892

  Anari, Shahram ^a,c   Carding, Paul N ^b   Hawthorne, Maurice R ^a   Deakin, Jayne ^a   Drinnan, Michael J ^b  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

Botulinum toxin; Quality of life; Spasmodic dysphonia

Indexed keywords

BOTULINUM TOXIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; DYSPHONIA; FEMALE; HUMAN; MALE; NEUROMUSCULAR BLOCKING; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SPASMODIC DYSPHONIA; STATISTICAL SIGNIFICANCE; VOICE; VOICE HANDICAP INDEX;

ADULT; AFFECT; AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; COHORT STUDIES; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; LARYNGEAL MUSCLES; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; VOICE DISORDERS; VOICE QUALITY;

EID: 34848825364     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLG.0b013e3180de4d63     Document Type: Article

References (20)

1. Hogikyan ND, Wodchis WP, Spak C, Kilney PR. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia. J Voice 2001;15:576-586.
2. Rubin AD, Wodchis WP, Spak C, Kilney PR, Hogikyan ND. Longitudinal effects of botulinum toxin injections on voicerelated quality of life (V-RQOL) for patients with adductory spasmodic dysphonia (Part II). Arch Otolarngol Head Neck Surg 2004;130:415-420.
3. Bhidayasiri R. Dystonia: genetics and treatment update. Neurologist 2006;12:74-85.
4. Kiese-Himmel C, Zwirner P. Psychological factors in spasmodic dysphonia. Laryngol Rhinol Otol 1996;75:397-402.
5. Troung DD, Rontal M, Rolnick M, Aronson AE, Mistura K. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 1991;101:630-634.
6. Adams SG, Durkin LC, Irish JC, Wong DL, Hunt EJ. Effects of botulinum toxin type A injections on aerodynamic measures of spasmodic dysphonia. Laryngoscope 1996;106:296-300.
7. Balash Y, Giladi N. Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effects of botulinum toxin and other cure options. Eur J Neurol 2004;11:361-370.
8. Watts C, Nye C, Whurr R. Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review. Clin Rehabil 2006;20:112-122.
9. Boutsen F, Cannito MP, Taylor M, Bender B. Botox treatment in adductor spasmodic dysphonia: a meta-analysis. J Speech Lang Hear Res 2002;45:469-481.
10. Blitzer A, Brin M, Stewart C. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 1998;108:1435-1441.
11. Wild D, Grove A, Martin M, et al. ISPOR Task Force for Translation and Cultural Adaptation. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes measures; report of the ISPOR Task Force for translation and cultural adaptation. Value Health 2005;8:94-104.
12. Bowden A, Fox-Rushby JA. A systematic and critical review of the process of translation and adaptation of generic health-related quality of life measures in Africa, Asia, Eastern Europe, the Middle East, and South America. Soc Sci Med 2003;57:1289-1306.
13. Jacobson BH, Johnson A, Grywalski C, et al. The Voice Handicap Index (VHI): development and validation. Am J Speech Lang Pathol 1997;6:66-70.
14. Breuer B, Sperber K, Wallenstein S, et al. Clinically significant placebo analgesic response in a pilot trial of botulinum B in patients with hand pain and carpal tunnel syndrome. Pain Med 2006;7:16-24.
15. Benninger MS, Gardner G, Grywalski C. Outcomes of botulinum toxin treatment for patients with spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 2001;127:1083-1085.
16. Langeveld TP, Luteijn F, van Rossum M, Drost HA, Baatenburg de Jong RJ. Adductor spasmodic dysphonia and botulinum toxin treatment: the effect on well-being. Ann Otol Rhinol Laryngol 2001;110:941-945.
17. Liu CY, Yu JM, Wang NM, et al. Emotional symptoms are secondary to the voice disorders in patients with spasmodic dysphonia. Gen Hosp Psychiatry 1998;20:255-259.
18. Cannito MP. Emotional considerations in spasmodic dysphonia: psychometric quantification. J Commun Disord 1991;24:313-329.
19. Wingate JM, Ruddy BH, Lundy DS, et al. Voice Handicap Index results for older patients with adductor spasmodic dysphonia. J Voice 2005;19:124-131.
20. Murry T, Cannito MP, Woodson GE. Spasmodic dysphonia. Emotional status and botulinum toxin treatment. Arch Otolaryngol Head Neck Surg 1994;120:310-316.